Fipamezole Transition from Biovail completed

Program Well Advanced Towards Phase III

21-Feb-2011 - Switzerland

Santhera Pharmaceuticals  announced that the transition of the fipamezole program back from Biovail was successfully completed. Fipamezole is being developed as a potential first treatment of dyskinesia in Parkinson's disease. During its partnership with Santhera and in preparation for Phase III development, Biovail generated additional data in numerous clinical and nonclinical studies. The additional data confirm and build upon the excellent profile of fipamezole established in two previous Phase II studies. The agreement was terminated following the merger between Valeant and Biovail. Santhera has the right to use all data generated by Biovail for further development and commercialization worldwide. Whilst it continues with the preparation for Phase III development, Santhera intends to license the US and Canadian rights to a new partner. Rights to fipamezole outside North America and Japan are licensed to Ipsen.

"An analysis of all data including those generated by Biovail confirms the excellent efficacy and safety profile of fipamezole. Importantly, the program has advanced very well since we entered the partnership in fall 2009. We continue to work towards initiation of the Phase III development", said Klaus Schollmeier, Chief Executive Officer of Santhera. "The high level of interest we are receiving for the North American rights confirms the medical and commercial attractiveness of this innovative drug. Fipamezole holds the potential to be the first approved therapy to treat Dyskinesia in Parkinson's Disease."

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Camena Bioscience closes $10m Series A financing as demand for DNA synthesis technology increases - Camena has also strengthened the Board of Directors with key appointments

Camena Bioscience closes $10m Series A financing as demand for DNA synthesis technology increases - Camena has also strengthened the Board of Directors with key appointments

New Phase II data show Novartis' ACZ885 gave better pain relief and flare prevention for patients with chronic gout

Celera Genomics Presents Preclinical Data on its Human Histone Deacetylase (HDAC) Inhibitor

New 'Chiral Vortex' of Light Reveals Molecular Mirror Images - The entirely new structure of light could help drug developers see their work more clearly than before

New 'Chiral Vortex' of Light Reveals Molecular Mirror Images - The entirely new structure of light could help drug developers see their work more clearly than before

Category:Canola_diseases

Measuring glucose concentration without enzymes - Sensor of novel material an alternative for blood glucose measurement

Measuring glucose concentration without enzymes - Sensor of novel material an alternative for blood glucose measurement

Univar Czech s.r.o. acquires enzymes distribution business of Ekozym

Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms - 'South-South' biotech collaborations boost health, economies: Study

Nanostructures in human teeth

Nanostructures in human teeth

Additional Data from Multiple Phase 1 and 2 Studies of S*BIO’s Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis - SB1518 Alleviates MF-Associated Splenomegaly and Shows No Myelosuppression and No Exacerbation of Cytopenias

Signs of dementia are written in the blood - 33 metabolic compounds linked to dementia could be key to new methods of diagnosis and treatment

Signs of dementia are written in the blood - 33 metabolic compounds linked to dementia could be key to new methods of diagnosis and treatment

Blood brain barrier gateway found